Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib + glofitamab for relapsed/refractory mantle cell lymphoma after prior BTK inhibitor
ACTRN12622001275752Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib and glofitamab in mantle cell lymphoma (MCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Complete response rate after 6 cycles. Started Oct 2023; status: recruiting.
02
Drugs
pirtobrutinibglofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ACTRN12622001275752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001275752.